ANAPTYSBIO, INC. Increase (Decrease) in Income Taxes Receivable
ANAPTYSBIO, INC. (ANAB) reported Increase (Decrease) in Income Taxes Receivable of $3.25 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2026-09-21
- ANAPTYSBIO, INC. increase (decrease) in income taxes receivable for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. increase (decrease) in income taxes receivable for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. increase (decrease) in income taxes receivable for the quarter ending 2019-06-30 was -$175.00K.
- ANAPTYSBIO, INC. increase (decrease) in income taxes receivable for the quarter ending 2019-03-31 was $1.00K, a 88.89% decline year-over-year.
- ANAPTYSBIO, INC. increase (decrease) in income taxes receivable for fiscal 2025 was $0.00.
- ANAPTYSBIO, INC. increase (decrease) in income taxes receivable for fiscal 2024 was $0.00.
- ANAPTYSBIO, INC. increase (decrease) in income taxes receivable for fiscal 2021 was $0.00.
- ANAPTYSBIO, INC. increase (decrease) in income taxes receivable for fiscal 2020 was $0.00.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.25M 10-KT · filed 2026-09-21 | |||
| 2025-12-31 | $0.00 10-KT · filed 2026-09-21 | |||
| 2025-06-30 | $0.00 10-KT · filed 2026-09-21 | |||
| 2024-12-31 | $0.00 10-KT · filed 2026-09-21 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-07 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-07 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $0.00 derived: sum of 2 quarters · filed 2022-03-07 | -$175.00K derived: sum of 3 quarters · filed 2022-03-07 | -$174.00K 10-K · filed 2022-03-07 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$175.00K derived: sum of 2 quarters · filed 2019-11-08 | -$174.00K 10-Q · filed 2019-11-08 | -$173.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$174.00K 10-Q · filed 2019-08-08 | -$173.00K derived: sum of 3 quarters · filed 2021-02-25 | -$152.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.00K 10-Q · filed 2019-05-07 | $2.00K derived: sum of 2 quarters · filed 2021-02-25 | $23.00K derived: sum of 3 quarters · filed 2021-02-25 | -$1.44M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $22.00K derived: sum of 2 quarters · filed 2021-02-25 | -$1.44M derived: sum of 3 quarters · filed 2021-02-25 | -$1.43M 10-K · filed 2021-02-25 |
| 2018-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$1.44M derived: sum of 2 quarters · filed 2019-11-08 | -$1.43M 10-Q · filed 2019-11-08 | -$1.31M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$1.45M 10-Q · filed 2019-08-08 | -$1.33M derived: sum of 3 quarters · filed 2020-03-02 | -$5.49M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $9.00K 10-Q · filed 2019-05-07 | $124.00K derived: sum of 2 quarters · filed 2020-03-02 | -$4.03M derived: sum of 3 quarters · filed 2020-03-02 | -$3.35M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$4.04M derived: sum of 2 quarters · filed 2020-03-02 | -$3.36M derived: sum of 3 quarters · filed 2020-03-02 | -$2.52M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$4.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$3.48M derived: sum of 2 quarters · filed 2018-11-08 | -$2.63M 10-Q · filed 2018-11-08 | -$1.81M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $672.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.52M 10-Q · filed 2018-08-07 | $2.34M derived: sum of 3 quarters · filed 2019-02-28 | $3.04M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $847.00K 10-Q · filed 2018-05-08 | $1.67M derived: sum of 2 quarters · filed 2019-02-28 | $2.37M derived: sum of 3 quarters · filed 2019-02-28 | $4.96M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $825.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.52M derived: sum of 2 quarters · filed 2019-02-28 | $4.12M derived: sum of 3 quarters · filed 2019-02-28 | $4.12M 10-K · filed 2019-02-28 |
| 2016-09-30 | $695.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.29M derived: sum of 2 quarters · filed 2017-11-07 | $3.29M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $2.60M 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |